D/E 1.11 — more levered than most Healthcare peers (≈90th pctile)
P/E13.6xA-
P/E 13.6 — cheaper than most Healthcare peers (≈25th pctile)
PEG0.69proxyA-
PEG 0.69 — strong; Lynch's preferred zone · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 86.9
Quality0.81
Growth1.00
Value0.81
Why this score
Buying back stock
Durable high returns
Earnings outpace cash
Entry · Margin of safety
52-week rangeNear 52-week low
55% off the 12-month high
vs DCF fair value31% belowest. fair value ~$13
Quality signals · context only
Gross profitability47% · A-gross profit ÷ total assets (Novy-Marx)
ROIC28.9% · Areturn on invested capital — not score-weighted
Why now
ADMA Biologics is a compounding machine, leveraging its specialty plasma-derived biologics like BIVIGAM and ASCENIV for primary humoral immunodeficiency (PI) to deliver exceptional profitable growth. With a robust 19.6% revenue growth and an impressive 32.4% profit margin, the company is generating substantial free cash flow of $108m on a modest 0.69 PEG ratio. The crux is the sustained demand for critical immune globulin products, which ADMA is efficiently scaling through its integrated BioManufacturing and Plasma Collection Centers.
Moat
ADMA's durable edge stems from its vertically integrated model, encompassing both ADMA BioManufacturing and Plasma Collection Centers, which ensures a controlled and reliable supply chain for its specialty plasma-derived biologics like BIVIGAM and ASCENIV. This operational control, coupled with the high regulatory hurdles and manufacturing complexity inherent in the biopharmaceutical sector, underpins its exceptional 42.4% Return on Equity, reflecting pricing power and efficiency in a critical healthcare niche. Competitors face significant capital and time barriers to replicate this integrated infrastructure.
Risk
The primary bear case centers on ADMA's elevated 1.11 Debt-to-Equity ratio, which could become a burden if growth in its specialty plasma-derived biologics market, particularly for IVIG products like BIVIGAM and ASCENIV, slows or faces increased competitive pricing pressure. A sustained deceleration in revenue growth below the current 19.6% or a contraction in profit margins would confirm that the company's debt load is becoming a material drag on equity value.
Horizon
1-3 yr $17.60 (5-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $22.22 at ~19% CAGR — dividend + buyback compounding. 10 yr $28.50 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · ADMA
$
%
%
Shares to buy
215
Position size
$1,993
4.0% of portfolio
Stop price
$6.95
25% below $9.27
$ at risk if stopped
$498.26
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
ADMA Biologics, Inc. (ADMA): score, valuation & FAQ
ADMA Biologics, Inc. (ADMA) is a Biotechnology company that scores 86.9 out of 100 on the Bull Rankings quality-growth model — a strong reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/E (A-), PEG (A-) and Rev (B+). On valuation, ADMA sits about 31% below our discounted-cash-flow fair value (a margin of safety).
Is ADMA a good stock to buy?
Bull Rankings scores ADMA 86.9 out of 100 on its quality-growth model, which is a strong reading. That is driven by P/E (A-), PEG (A-) and Rev (B+). A score is a quantitative screen of ADMA Biologics, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does ADMA score 86.9 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). ADMA earns its highest marks on P/E (A-), PEG (A-) and Rev (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is ADMA overvalued or undervalued?
Based on $9.27, ADMA sits about 31% below our discounted-cash-flow fair value (a margin of safety). It trades at a 13.6x× P/E (graded A-). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in ADMA?
The primary bear case centers on ADMA's elevated 1.11 Debt-to-Equity ratio, which could become a burden if growth in its specialty plasma-derived biologics market, particularly for IVIG products like BIVIGAM and ASCENIV, slows or faces increased competitive pricing pressure. A sustained deceleration in revenue growth below the current 19.6% or a contraction in profit margins would confirm that the company's debt load is becoming a material drag on equity value.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.